Genmab A/S GMAB
51.35 USD +0.38 (+0.75%)
Regular-session close
51.30 -0.05 -0.10%
After hours · Nov 19, 7:06 PM ET
51.06 Day range 52.40
23.62 52-week range 59.97
- YTD
- +66.72%
- 1 year
- +67.98%
News
globenewswire.com Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 18, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 4,993 restricted stock units and 4,607 warrants to…benzinga.com Morgan Stanley Maintains Equal-Weight on Genmab, Lowers Price Target to $56 Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and lowers the price target from $57 to $56.
fool.com Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
globenewswire.com Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; November 11, 2026 - Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation…
globenewswire.com Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation…
globenewswire.com Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The…
seekingalpha.com Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript Genmab A/S (GMAB) Q3 2026 Earnings Call Transcriptbenzinga.com Genmab Q3 EPS $5.51 Beats $3.59 Estimate, Sales $1.187B Miss $1.194B Estimate Genmab (NASDAQ:GMAB) reported quarterly earnings of $5.51 per share which beat the analyst consensus estimate of $3.59 by 53.48 percent. This is a 14.71 percent decrease over earnings of $6.46 per…
benzinga.com Genmab Affirms FY2026 Sales Guidance of $4.325B-$4.525B vs $4.472B Est Genmab (NASDAQ:GMAB) affirms FY2026 sales outlook from $4.325 billion-$4.525 billion to $4.325 billion-$4.525 billion vs $4.472 billion estimate.
marketbeat.com What Genmab A/S (GMAB) Said on Its Q3 Earnings Call Genmab A/S NASDAQ: GMAB reported 22% revenue growth for the first nine months of 2026 and said it expects full-year revenue to land in the upper part of its existing guidance range, as sales of…
benzinga.com Genmab Q3 2026 Earnings Call Transcript Genmab (NASDAQ:GMAB) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
globenewswire.com Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting Media Release COPENHAGEN, Denmark; November 4, 2026 Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier…
cnbc.com A little-known biotech's high-stakes cancer bet just paid off and its shares doubled Genmab shares have doubled in three months after three successful Phase 3 cancer drug trials in October. The Danish biotech is using royalty income from drugs such as Darzalex to fund a shift toward…benzinga.com Morgan Stanley Maintains Equal-Weight on Genmab, Raises Price Target to $57 Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and raises the price target from $42 to $57.
benzinga.com Guggenheim Maintains Buy on Genmab, Raises Price Target to $80 Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $58 to $80.
benzinga.com Truist Securities Reiterates Buy on Genmab, Raises Price Target to $67 Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $67.
benzinga.com HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $70 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $50 to $70.
seekingalpha.com Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript
marketbeat.com Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the…
benzinga.com Genmab Stock Hits 52-Week High - Here's Why Genmab shares gain as petosemtamab cuts head and neck cancer death risk by 50%, backing William Blair's $8 billion peak sales projections.
benzinga.com Genmab Stock Hits 52-Week High - Here's Why Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline findings from its global Phase 3 LiGeR-HN1 clinical trial evaluating petosemtamab, an…
barrons.com Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50% Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.benzinga.com Genmab A/S Announces Data From Its Phase 3 LiGeR-HN1 Study Of Petosemtamab Demonstrates 50% Death Risk Reduction For Treatment Of Head And Neck Squamous Cell Carcinoma Genmab A/S (NASDAQ:GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting…
businesswire.com Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an…
globenewswire.com Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer Company Announcement COPENHAGEN, Denmark; October 28, 2026 Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing…benzinga.com TD Cowen Maintains Buy on Genmab, Raises Price Target to $52 TD Cowen analyst Yaron Werber maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $43 to $52.
zacks.com Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
benzinga.com Genmab's Encouraging Oncology Data Boosts Investor Optimism Biotechnology company Genmab A/S (NASDAQ:GMAB) delivered encouraging clinical updates for its investigational bispecific antibody petosemtamab across two major solid tumor types at the European…
benzinga.com Genmab's Encouraging Oncology Data Boosts Investor Optimism Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners with Incyte on targeted colorectal therapy.
wsj.com Genmab Shares Jump After Positive Cancer Study Results The Danish biotech said an experimental drug cut the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial.benzinga.com Genmab Presents Updated Phase 2 Data For Petosemtamab Plus Pembrolizumab In First-Line PD-L1–Positive Recurrent/Metastatic Head And Neck Cancer, At ESMO Congress 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell…
globenewswire.com Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Media Release COPENHAGEN, Denmark; October 26, 2026 Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L)…benzinga.com Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to…
